HomeCompareBRYAF vs ABBV

BRYAF vs ABBV: Dividend Comparison 2026

BRYAF yields 2976.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRYAF wins by $421400563152.00M in total portfolio value
10 years
BRYAF
BRYAF
● Live price
2976.19%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$421400563152.10M
Annual income
$395,274,393,919,294,200.00
Full BRYAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BRYAF vs ABBV

📍 BRYAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRYAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRYAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRYAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRYAF
Annual income on $10K today (after 15% tax)
$252,976.19/yr
After 10yr DRIP, annual income (after tax)
$335,983,234,831,400,060.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BRYAF beats the other by $335,983,234,831,379,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRYAF + ABBV for your $10,000?

BRYAF: 50%ABBV: 50%
100% ABBV50/50100% BRYAF
Portfolio after 10yr
$210700281576.10M
Annual income
$197,637,196,959,659,500.00/yr
Blended yield
93.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BRYAF
No analyst data
Altman Z
0.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRYAF buys
0
ABBV buys
0
No recent congressional trades found for BRYAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRYAFABBV
Forward yield2976.19%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$421400563152.10M$102.3K
Annual income after 10y$395,274,393,919,294,200.00$24,771.77
Total dividends collected$419593464043.04M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRYAF vs ABBV ($10,000, DRIP)

YearBRYAF PortfolioBRYAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$308,319$297,619.05$11,550$430.00+$296.8KBRYAF
2$8,905,754$8,575,852.46$13,472$627.96+$8.89MBRYAF
3$241,036,011$231,506,854.42$15,906$926.08+$241.02MBRYAF
4$6,113,777,105$5,855,868,573.20$19,071$1,382.55+$6113.76MBRYAF
5$145,356,362,959$138,814,621,456.31$23,302$2,095.81+$145356.34MBRYAF
6$3,239,968,150,316$3,084,436,841,950.57$29,150$3,237.93+$3239968.12MBRYAF
7$67,720,563,015,376$64,253,797,094,537.52$37,536$5,121.41+$67720562.98MBRYAF
8$1,327,608,714,870,041$1,255,147,712,443,588.80$50,079$8,338.38+$1327608714.82MBRYAF
9$24,416,980,591,406,588$22,996,439,266,495,650.00$69,753$14,065.80+$24416980591.34MBRYAF
10$421,400,563,152,099,260$395,274,393,919,294,200.00$102,337$24,771.77+$421400563152.00MBRYAF

BRYAF vs ABBV: Complete Analysis 2026

BRYAFStock

Berjaya Corporation Berhad provides consumer marketing, direct selling, and retailing services in Malaysia and internationally. It also engages in the financial services; hotels, resorts, vacation timeshare, and recreation development and operation; property investment, development, and management; gaming and lottery management; food and beverage; and telecommunication and information technology-related services, solutions, and products businesses. In addition, the company produces, trades in, distributes, and rents motor vehicles; operates clubs; produces and supplies potable water; operates book stores and a private university college; operates and franchises restaurants and cafes; and provides digital media marketing, management, educational, training, consultancy, real estate agency and valuation, and civil engineering contracting services. Further, it promotes and operates esports; owns and operates pharmacy stores; imports, trades in, distributes, markets, and retails products sold in pharmacies, and health and beauty retailers; collects, transports, stores, treats, recovers, disposes, and manages hazardous and toxic, and medical waste; and offers securities and printing, information technology consultancy, medical laboratory, investment advisory, asset and fund management, hire purchase, loan financing, money lending, stock and share broking, nominee, environmental engineering and river cleaning, interior design, security, jet charter, aircraft leasing, spa management, casino, insurance agency, telecommunications, system integration, logistics, warehousing, and courier services. Additionally, it engages in the sanitary landfills; wearing apparel retail; household, personal and healthcare, consumer, and skin care products; organic food; electricity generation; computer hardware trading; palm oil and kernel; and travel and tour agency businesses. The company was founded in 1984 and is based in Kuala Lumpur, Malaysia.

Full BRYAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BRYAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRYAF vs SCHDBRYAF vs JEPIBRYAF vs OBRYAF vs KOBRYAF vs MAINBRYAF vs JNJBRYAF vs MRKBRYAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.